JP2021511326A5 - - Google Patents
Info
- Publication number
- JP2021511326A5 JP2021511326A5 JP2020539792A JP2020539792A JP2021511326A5 JP 2021511326 A5 JP2021511326 A5 JP 2021511326A5 JP 2020539792 A JP2020539792 A JP 2020539792A JP 2020539792 A JP2020539792 A JP 2020539792A JP 2021511326 A5 JP2021511326 A5 JP 2021511326A5
- Authority
- JP
- Japan
- Prior art keywords
- mtg
- monothioglycerol
- ascorbic acid
- acid
- combination
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862620317P | 2018-01-22 | 2018-01-22 | |
| US62/620,317 | 2018-01-22 | ||
| PCT/US2019/014422 WO2019144079A1 (en) | 2018-01-22 | 2019-01-21 | Pharmaceutical composition for sustained release delivery of buprenorphine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021511326A JP2021511326A (ja) | 2021-05-06 |
| JPWO2019144079A5 JPWO2019144079A5 (https=) | 2022-01-31 |
| JP2021511326A5 true JP2021511326A5 (https=) | 2022-01-31 |
Family
ID=67301573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020539792A Pending JP2021511326A (ja) | 2018-01-22 | 2019-01-21 | ブプレノルフィンの徐放送達のための薬学的組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11419866B2 (https=) |
| EP (1) | EP3743072B1 (https=) |
| JP (1) | JP2021511326A (https=) |
| CN (1) | CN112236142A (https=) |
| AU (1) | AU2019209416A1 (https=) |
| CA (1) | CA3089114A1 (https=) |
| ES (1) | ES2965836T3 (https=) |
| TW (1) | TW201936191A (https=) |
| WO (1) | WO2019144079A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230080811A1 (en) * | 2020-01-14 | 2023-03-16 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Long-acting ropivacaine pharmaceutical composition, preparation method therefor and use thereof |
| CN113117092A (zh) * | 2020-01-14 | 2021-07-16 | 中国科学院上海药物研究所 | 一种非水缓释递药系统 |
| WO2022175974A1 (en) * | 2021-02-18 | 2022-08-25 | Navin Saxena Research And Technology Private Limited | Non-aqueous injectable composition for sustained release of buprenorphine and use thereof |
| IL317873A (en) * | 2022-06-24 | 2025-02-01 | Alar Pharmaceuticals Inc | Stable pharmaceutical composition of buprenorphine and method of preparation and use thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8533582A (en) * | 1981-07-10 | 1984-01-12 | Reckitt & Colman Products Limited | Stable solutions of buprenorphine |
| US4626539A (en) | 1984-08-10 | 1986-12-02 | E. I. Dupont De Nemours And Company | Trandermal delivery of opioids |
| CA2002299A1 (en) * | 1988-11-10 | 1990-05-10 | Eugene G. Drust | Compositions for the transdermal delivery of buprenorphine salts |
| IT1302682B1 (it) | 1998-10-16 | 2000-09-29 | Formenti Farmaceutici Spa | Composizioni farmaceutiche orali contenenti buprenorfina |
| DE60329515D1 (de) | 2002-10-25 | 2009-11-12 | Euro Celtique Sa | Analoga und prodrugs von buprenorphin |
| CN1263760C (zh) | 2002-11-12 | 2006-07-12 | 财团法人奇美医院 | 新颖的丁丙诺啡酯衍生物及其制备方法，以及长效作用镇痛药学组合物 |
| WO2005117830A1 (en) * | 2004-06-04 | 2005-12-15 | Camurus Ab | Liquid depot formulations |
| RU2008124805A (ru) * | 2005-11-21 | 2009-12-27 | Шеринг-Плоу Лтд. (CH) | Фармацевтические композиции, содержащие бупренорфин |
| US20090270438A1 (en) * | 2006-10-18 | 2009-10-29 | Clive Booles | Novel compositions and formulations |
| EP2262367A4 (en) * | 2008-03-08 | 2011-04-20 | Theraquest Biosciences Inc | PHARMACEUTICAL ORAL COMPOSITIONS OF BUPRENORPHINE AND METHOD FOR THEIR USE |
| WO2009148503A2 (en) | 2008-05-30 | 2009-12-10 | Namedepot.Com, Inc. | Method and system for providing online services and software |
| GB0815435D0 (en) * | 2008-08-22 | 2008-10-01 | Camurus Ab | Formulations |
| GB2481018B (en) | 2010-06-08 | 2015-03-18 | Rb Pharmaceuticals Ltd | Injectable flowable composition comprising buprenorphine |
| GB2481017B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| EP2611445B1 (en) * | 2010-09-03 | 2018-08-15 | Zoetis Belgium S.A. | High dose buprenorphine compositions and use as analgesic |
| EP3791861A1 (en) | 2012-07-26 | 2021-03-17 | Camurus AB | Opioid formulations |
| US9918981B2 (en) * | 2013-09-10 | 2018-03-20 | Insys Development Company, Inc. | Liquid buprenorphine formulations |
| GB201404139D0 (en) * | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| NZ731309A (en) | 2014-11-07 | 2022-02-25 | Indivior Uk Ltd | Buprenorphine dosing regimens |
-
2019
- 2019-01-21 EP EP19741052.5A patent/EP3743072B1/en active Active
- 2019-01-21 JP JP2020539792A patent/JP2021511326A/ja active Pending
- 2019-01-21 AU AU2019209416A patent/AU2019209416A1/en not_active Abandoned
- 2019-01-21 US US16/962,040 patent/US11419866B2/en active Active
- 2019-01-21 CN CN201980009501.7A patent/CN112236142A/zh active Pending
- 2019-01-21 ES ES19741052T patent/ES2965836T3/es active Active
- 2019-01-21 CA CA3089114A patent/CA3089114A1/en active Pending
- 2019-01-21 WO PCT/US2019/014422 patent/WO2019144079A1/en not_active Ceased
- 2019-01-22 TW TW108102619A patent/TW201936191A/zh unknown